Medical Advisory Board: Dr. Ram Dandillaya, Clinical Chief, Cardiology, Cedars-Sinai; Dr. Antonio J. Forte, Faculty, Mayo Clinic; Dr. Rinn Song, Fmr. Faculty, Harvard Medical School; Dr. Daniel Kahneman, Nobel Prize Laureate. OpenEvidence is a Mayo Clinic Platform Accelerate Company.
Clinical Evidence for Efficacy & Safety of FDA-Approved Psoriasis TreatmentsA Living Systematic Meta-Analysis
More Like This
Clinical Efficacy of Treatments for Psoriasis: OpenEvidence Meta-Analysis
A summary of OpenEvidence's systematic meta-analysis of the efficacy of treatments for psoriasis is shown below. Efficacy is measured by the percentage of participants achieving Psoriasis Area and Severity Index 75% (PASI75) response, and data is aggregated from peer-reviewed clinical trials. Non-FDA-approved treatments and treatments without available data are excluded.[1-18]
Response rate distributions are computed with a random effects model, using data from the largest randomized controlled trials published in the highest-impact peer-reviewed scientific journals. Publications that report the percentage of participants achieving Psoriasis Area and Severity Index 75% (PASI75) response between 8 - 24 weeks are included in the analysis. The bar values represent the best estimate of the mean and error-bars represent 95% confidence intervals. Note that the above figure only shows patient response rates and does not include other clinically relevant measures such as side effects.
Clinical Efficacy of Treatments for Psoriasis: OpenEvidence Meta-Analysis
A summary of OpenEvidence's systematic meta-analysis of the efficacy of treatments for psoriasis is shown below. Efficacy is measured by the percentage of participants achieving Psoriasis Area and Severity Index 75% (PASI75) response, and data is aggregated from peer-reviewed clinical trials. Non-FDA-approved treatments and treatments without available data are excluded.[1-18]
Response rate distributions are computed with a random effects model, using data from the largest randomized controlled trials published in the highest-impact peer-reviewed scientific journals. Publications that report the percentage of participants achieving Psoriasis Area and Severity Index 75% (PASI75) response between 8 - 24 weeks are included in the analysis. The bar values represent the best estimate of the mean and error-bars represent 95% confidence intervals. Note that the above figure only shows patient response rates and does not include other clinically relevant measures such as side effects.
American Academy of Dermatology Guidelines
Psoriasis is a multifaceted condition, and different people have different experiences with it. Beyond clinical efficacy, treatment history, disease presentation, co-occuring conditions, patient population, and other factors play a role in determining a treatment plan. It is important to consult a healthcare professional or specialist to learn about individual considerations and to develop a specialized treatment plan.
More information about individual considerations can be found in the clinical guidelines from the American Academy of Dermatology.
Understanding Psoriasis
Psoriasis is a chronic (long-lasting) disease in which the immune system becomes overactive, causing skin cells to multiply too quickly. Patches of skin become scaly and inflamed, most often on the scalp, elbows, or knees, but other parts of the body can be affected as well. Scientists do not fully understand what causes psoriasis, but they know that it involves a mix of genetics and environmental factors. Anyone can get psoriasis, but it is more common in adults than in children. It affects men and women equally. Symptoms of psoriasis vary from person to person, but some common ones include:
- Patches of thick, red skin with silvery-white scales that itch or burn, typically on the elbows, knees, scalp, trunk, palms, and soles of the feet.
- Dry, cracked skin that itches or bleeds.
- Thick, ridged, pitted nails.
Source: National Institute of Arthritis and Musculoskeletal and Skin Diseases
Was this page informative?
References
1. Lebwohl MG, Stein Gold L, Strober B, et al. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. The New England Journal of Medicine. 2021;385(24):2219-2229. doi:10.1056/NEJMoa2103629.
2. Lebwohl MG, Kircik LH, Moore AY, et al. Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials. Jama. 2022;328(11):1073-1084. doi:10.1001/jama.2022.15632.
3. Reich K, Gooderham M, Green L, et al. The Efficacy and Safety of Apremilast, Etanercept and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis: 52-Week Results From a Phase IIIb, Randomized, Placebo-Controlled Trial (LIBERATE). Journal of the European Academy of Dermatology and Venereology : JEADV. 2017;31(3):507-517. doi:10.1111/jdv.14015.
4. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and Safety Results From the Randomized Controlled Comparative Study of Adalimumab vs. Methotrexate vs. Placebo in Patients With Psoriasis (CHAMPION). The British Journal of Dermatology. 2008;158(3):558-66. doi:10.1111/j.1365-2133.2007.08315.x.
5. Reich K, Armstrong AW, Langley RG, et al. Guselkumab Versus Secukinumab for the Treatment of Moderate-to-Severe Psoriasis (ECLIPSE): Results From a Phase 3, Randomised Controlled Trial. Lancet (London, England). 2019;394(10201):831-839. doi:10.1016/S0140-6736(19)31773-8.
6. Reich K, Gordon KB, Strober BE, et al. Five-Year Maintenance of Clinical Response and Health-Related Quality of Life Improvements in Patients With Moderate-to-Severe Psoriasis Treated With Guselkumab: Results From VOYAGE 1 and VOYAGE 2. The British Journal of Dermatology. 2021;185(6):1146-1159. doi:10.1111/bjd.20568.
7. Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. The New England Journal of Medicine. 2016;375(4):345-56. doi:10.1056/NEJMoa1512711.
8. Gordon KB, Strober B, Lebwohl M, et al. Efficacy and Safety of Risankizumab in Moderate-to-Severe Plaque Psoriasis (UltIMMa-1 and UltIMMa-2): Results From Two Double-Blind, Randomised, Placebo-Controlled and Ustekinumab-Controlled Phase 3 Trials. Lancet (London, England). 2018;392(10148):650-661. doi:10.1016/S0140-6736(18)31713-6.
9. Lebwohl M, Strober B, Menter A, et al. Phase 3 Studies Comparing Brodalumab With Ustekinumab in Psoriasis. The New England Journal of Medicine. 2015;373(14):1318-28. doi:10.1056/NEJMoa1503824.
10. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in Plaque Psoriasis--Results of Two Phase 3 Trials. The New England Journal of Medicine. 2014;371(4):326-38. doi:10.1056/NEJMoa1314258.
11. Reich K, Nestle FO, Papp K, et al. Infliximab Induction and Maintenance Therapy for Moderate-to-Severe Psoriasis: A Phase III, Multicentre, Double-Blind Trial. Lancet (London, England). 2005 Oct 15-21;366(9494):1367-74. doi:10.1016/S0140-6736(05)67566-6.
12. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and Safety of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Psoriasis: 52-Week Results From a Randomised, Double-Blind, Placebo-Controlled Trial (PHOENIX 2). Lancet (London, England). 2008;371(9625):1675-84. doi:10.1016/S0140-6736(08)60726-6.
13. Lebwohl M, Blauvelt A, Paul C, et al. Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: Results Through 48 weeks of a Phase 3, Multicenter, Randomized, Double-Blind, Etanercept- And Placebo-Controlled Study (CIMPACT). Journal of the American Academy of Dermatology. 2018;79(2):266-276.e5. doi:10.1016/j.jaad.2018.04.013.
14. Gottlieb AB, Blauvelt A, Thaçi D, et al. Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: Results Through 48 weeks From 2 Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2). Journal of the American Academy of Dermatology. 2018;79(2):302-314.e6. doi:10.1016/j.jaad.2018.04.012.
15. Menter A, Tyring SK, Gordon K, et al. Adalimumab Therapy for Moderate to Severe Psoriasis: A Randomized, Controlled Phase III Trial. Journal of the American Academy of Dermatology. 2008;58(1):106-15. doi:10.1016/j.jaad.2007.09.010.
16. Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab Versus Placebo or Etanercept for Chronic Plaque Psoriasis (reSURFACE 1 and reSURFACE 2): Results From Two Randomised Controlled, Phase 3 Trials. Lancet (London, England). 2017;390(10091):276-288. doi:10.1016/S0140-6736(17)31279-5.
17. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as Monotherapy in Patients With Psoriasis. The New England Journal of Medicine. 2003;349(21):2014-22. doi:10.1056/NEJMoa030409.
18. Sterry W, Ortonne JP, Kirkham B, et al. Comparison of Two Etanercept Regimens for Treatment of Psoriasis and Psoriatic Arthritis: PRESTA Randomised Double Blind Multicentre Trial. BMJ (Clinical Research Ed.). 2010;340:c147. doi:10.1136/bmj.c147.